Zymeworks Launches Phase 1 Trial for ZW191
Company Announcements

Zymeworks Launches Phase 1 Trial for ZW191

Story Highlights

Zymeworks (ZYME) has released an update.

Zymeworks Inc. has begun a Phase 1 clinical trial to test the safety and tolerability of ZW191, a new antibody-drug conjugate, in treating advanced cancers such as ovarian, endometrial, and non-small cell lung cancers. This trial marks a significant step for Zymeworks in their mission to provide innovative treatments for difficult-to-treat cancers. The study will enroll 145 patients globally, with the goal of advancing Zymeworks’ robust pipeline of therapeutic candidates.

For further insights into ZYME stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyZymeworks says first patient dosed in Phase 1 trial of ZW191
TheFlyZymeworks price target raised to $18 from $16 at Citi
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App